| Affiliation: | 1. McGill University, and the Research Institute of McGill University Health Center, Montreal, Canada;2. Dr. Rahme has received consultancy fees (more than $10,000) from Merck, Pfizer, and Boehringer Ingelheim. Dr. Barkun has received consultancy fees and/or honoraria (less than $10,000) from Merck & Co., Inc., Altana Canada, and from AstraZeneca (more than $10,000). Dr. Scalera owns stock in Pfizer. Ms Rochon owns stock and options in Pfizer and has received grant support from Pfizer Canada, Inc.;3. Dr. LeLorier has received consultancy fees and/or honoraria (more than $10,000 each) from Bristol‐Myers Squibb, Merck Frosst, Pfizer, Janssen‐Ortho, Sanofi‐Aventis, GlaxoSmithKline, Eli Lilly, Wyeth, and Boehringer Ingelheim, and has given expert testimony for Merck Frosst. Drs. Rahme, Barkun, and LeLorier have received grants from Merck, the previous manufacturer of rofecoxib. Drs. Rahme and LeLorier have also received funds from Pfizer, the manufacturer of celecoxib and from Boehringer Ingelheim, the manufacturer of meloxicam.;4. Outcomes Research, Pfizer Canada, Inc., Montreal, Canada;5. Montreal University and Centre de Recherche Centre Hospitalier de l'Université de Montréal, H?tel‐Dieu, Montreal, Canada |
